12-Month Lobbying Summary - In-house Organization

• Subject matter details in previous versions

  Details Regarding the Identified Subject Matter

  Subject matters	Details	Categories
  Subject matters were not required to be associated with subject matter details when this content was submitted	ACCESS & BENEFIT SHARING: TRIPS AGREEMENT in respect of protecting intellectual property and preventing increased uncertainty	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	ADVENTITIOUS PRESCENCE POLICY in respect of new agricultural biotechnology products	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	BIOSAFETY PROTOCOL in respect of Canada's participation in global discussions to ensure an enabling environment for safe new technologies	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	CANADIAN ENVIRONMENTAL PROTECTION ACT AND REGULATIONS in respect of modern, science-based regulations to reflect rapidly changing new technologies	Legislative Proposal, Bill or Resolution, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Clarify the administration of SR&ED program to ensure clinical trials and international research conducted in Canada qualifies as eligible expenses	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Creation of a modern policy environment that recognizes international standards and reviews, and establishes clarity on data ownership for intellectual property	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Establish accountability with the federally financed Canadian Agency for Drugs and Technologies and Health (CADTH) and its Common Drug Review process (Health Canada)	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	FOOD AND DRUGS ACT AND REGULATIONS in respect of minimizing regulatory burden and ensuring appropriate climate for the introduction of new technologies	Legislative Proposal, Bill or Resolution, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	FOOD LABELLING in respect of mitigating the unnecessary introduction of new labelling requirements for products already approved under current regulated process and in respect of maintaining harmonization of requirements with trading nations	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	IMPROVED TAXATION & INVESTMENT FRAMEWORK in respect of extending Canada's flow-through shares program to biotechnology companies for increased domestic investments.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	IMPROVEMENTS TO THE Scientifc Research & Experimental Development TAX CREDITS in respect of updating the 20 yr old system by removing the punitive Canadian Controlled Private Companies restriction and increasing the expenditure limit for refundable credits	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	INTELLECTUAL PROPERTY/PATENT POLICY AND REGULATIONS in respect of creating Canada as one of the world's most competitive jurisdictions in protecting IP (e.g., match level of European Union via CETA negotiations)	Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	NOVEL FOODS in respect of maintaining a science-based regulatory system for novel foods derived from plant and animal biotechnology	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	ORPHAN PRODUCTS to establish formal regulations, policies or programs to encourage the research, development and introduction of new technologies to treat "orphan" or neglected diseases	Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	PATENTED MEDECINES PRICES REVIEW BOARD (PMPRB) PRICE REVIEW to ensure new guidelines and directives do not create disincentives for the introduction of new treatments in Canada	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	REGULATORY APPROVAL PROCESS FOR PLANTS WITH NOVEL TRAITS as NOVEL FOODS or INDUSTRIAL BIO_PRODUCTS in respect of an efficient science-based approach and allows for greater cooperation among and between government departments	Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	RESEARCH & DEVELOPMENT (R&D) in respect on providing input to the government's expert panel on business R&D to improve incentives for research in Canada	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Regulatory framework for subsequent entry biologics to ensure an appropriate and transparent appraoch for the safe introduction of biosimilars	Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	SCIENCE & TECHNOLOGY STRATEGY in respect of encouraging a strong government focus to stimulate the development, use and retention of biotechnology products, processes and companies	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	SUBMISSION REVIEW PROCESS FOR BIOLOGICS, COST RECOVERY REVIEW to ensure Canada remains competitive overall and any new costs do not put bioloigics are a comparative disadvantage	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	SUBSEQUENT ENTRY BIOLOGICS to establish formal regulations to prescribe the requirements for introduction of biosimilars and ensure the protection of intellectual property for first entry biologics	Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Vaccine Funding - National Immunization Strategy - to re-establish federal leadership in providing provinces with funding for new vaccines under a renewed national immunization strategy framework	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Vaccine contracting and supply	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	WORLD TRADE ORGANIZATION (WTO) in respect of Canada's contribution and participation to encourage a sound business climate and to faciliate Canada's access to European markets for genetically engineered agricultural and animal products	Policies or Program

  Subject matters in previous versions

  • Agriculture
  • Budget
  • Consumer Issues
  • Economic Development
  • Employment and Training
  • Energy
  • Environment
  • Fisheries
  • Forestry
  • Government Procurement
  • Health
  • Immigration
  • Industry
  • Intellectual Property
  • International Relations
  • International Trade
  • Research and Development
  • Science and Technology
  • Small Business
  • Taxation and Finance

Government Institutions

• Agriculture and Agri-Food Canada (AAFC)
• Atlantic Canada Opportunities Agency (ACOA)
• Business Development Bank of Canada (BDC)
• Canada Economic Development for Quebec Regions
• Canada Pension Plan Investment Board
• Canada Revenue Agency (CRA)
• Canadian Food Inspection Agency (CFIA)
• Canadian Institutes of Health Research (CIHR)
• Employment and Social Development Canada (ESDC)
• Environment and Climate Change Canada (ECCC)
• Export Development Canada (EDC)
• Federal Economic Development Agency for Southern Ontario (FedDev)
• Finance Canada (FIN)
• Fisheries and Oceans Canada (DFO)
• Global Affairs Canada (GAC)
• Health Canada (HC)
• House of Commons
• Immigration, Refugees and Citizenship Canada (IRCC)
• Innovation, Science and Economic Development Canada (ISED)
• National Research Council (NRC)
• Natural Resources Canada (NRCan)
• Natural Sciences and Engineering Research Council (NSERC)
• Patented Medicine Prices Review Board (PMPRB)
• Prime Minister's Office (PMO)
• Privy Council Office (PCO)
• Public Health Agency of Canada (PHAC)
• Senate of Canada
• Social Sciences and Humanities Research Council (SSHRC)
• Statistics Canada (StatCan)
• Treasury Board Of Canada Secretariat (TBS)

Communication techniques

Communication techniques that have been used or are expected to be used in the course of the undertaking:

• Grass-roots communication
• Written communication
• Oral communication
• Arrange one or more meetings

• ANDREW CASEY, President & CEO | Public offices held
• Ron Boch, VP, Biotechnology & Industry Affairs | No public offices held
• Pascale Lajoie Kostka, Director, Health Policy | No public offices held
• CATE MCCREADY, VP, EXTERNAL AFFAIRS | Public offices held
• Emily Meyers, Co-ordinator Membership Services | No public offices held

• Lobbyists in previous versions

  • Nadine Lunt, Sr Mgr, Communications | No public offices held